Clinical Trial Update: Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability update for AlloVax in metastatic or recurrent head and neck cancer (squamous cell carcinoma) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer of the Head and Neck
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• AlloVax

Snippet

Sponsor: Mirror Biologics, Inc. | Conditions: Cancer of Head and Neck, Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: COMPLETED